Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-1 plus temozolomide vs temozolomide ± cisplatin in recurrent high-grade glioma (Phase II, China)
ChiCTR2500100550Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of SM-1 in glioma (4 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Brain glioma lesion measurement. Started Apr 2025; status: recruiting.
02
Drugs
SM-1
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2500100550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100550.